Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Multiple studies have demonstrated beneficial reductions in weight and HbA 1c with short acting GLP-1 RA in individuals with overweight or obesity and type 1 diabetes [45,46,47,48]
In Phase 2, the 12 mg group lost an average of 24.2% body weight over 48 weeks
Product offer terms are subject to change
The Key Risk: Euglycemic DKA One of the most serious concerns with GLP-1 use in Type 1 diabetes is euglycemic DKA a form of diabetic ketoacidosis where blood glucose may not be severely elevated
US$ 24.12
US$ 28.75
US$ 27.16
US$ 20.20
US$ 28.43
US$ 28.46
